| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA274: Ranibizumab for treating diabetic macular oedema (replaced TA237) |
|
Medicine details |
|
| Medicine name | ranibizumab (Lucentis®) |
| Formulation | 10 mg/ml solution for injection |
| Reference number | 552 |
| Indication | Treatment of visual impairment due to diabetic macular oedema |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Eye |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 23/12/2010 |
| NICE guidance | TA274: Ranibizumab for treating diabetic macular oedema (replaced TA237) |